https://www.selleckchem.com/pr....oducts/tipranavir.ht
018), indicating that Glx levels decreased in infliximab-treated patients, relative to placebo. Treatment group significantly moderated the association between changes in Glx levels and changes in a neurocognitive test (i.e. Digit Symbol Substitution Test; p=0.014), indicating that in infliximab-treated participants reductions in Glx were associated with cognitive improvement. Treatment with infliximab did not affect prefrontal NAA concentration in adults with BD. Exploratory analysis suggested a potential effect of treatment on the
Like
Comment
Share
